US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

The Aaron's Company, Inc.

10.09

0.0000

Volume:- -

Turnover:- -

Market Cap:309.89M

PE:-7.25

High:10.09

Open:10.09

Low:10.09

Close:10.09

Loading ...

Overview Company News Filings

Press Release: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Press Release: Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AAN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","market":"US","secType":"STK","nameCN":"The Aaron's Company, Inc.","latestPrice":10.09,"timestamp":1749064213883,"preClose":10.09,"halted":0,"volume":0,"delay":0,"floatShares":29872074,"shares":30712772,"eps":-1.391109,"marketStatus":"Trading","change":0,"latestTime":"06-04 15:10:13 EDT","open":10.09,"high":10.09,"low":10.09,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.391109,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749067200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.09,"dividendRate":0.049554,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","floatShares":29872074,"roa":"2.18%","roe":"-6.22%","lyrEps":0.091721,"shares":30712772,"dividePrice":0.5,"high":10.09,"amplitude":0,"preClose":10.09,"low":10.09,"week52Low":6.622,"pbRate":"0.47","psRate":"0.15","week52High":11.9,"institutionHeld":0.9259,"latestPrice":10.09,"eps":-1.391109,"divideRate":0.049554,"volume":0,"delay":0,"ttmEps":-1.391109,"open":10.09,"prevYearClose":10.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535042289","title":"Press Release: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042289","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042289?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"-- Advancing a broad, potential best-in-class orexin receptor 2 . agonist franchise, with key data readouts expected this year. -- ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy. type 1 , narcolepsy type 2  and idiopathic hypersomnia.  on track with data expected across all three indications this. -- ORX142 on track to initiate first-in-human studies for the. clinical data in acutely sleep-deprived healthy volunteers planned. BOSTON and LONDON, May 14, 2025  -- Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company, today reported financial results and business highlights for the first quarter ended March 31, 2025.Dr. Saha continued, \"We are excited to be at the forefront of developing OX2R agonists starting with ORX750, our most advanced OX2R agonist for the treatment of NT1, NT2 and IH. ORX750 is progressing in the Phase 2a CRYSTAL-1 study and is on track with patient data expected across all three indications this year. Given the unmet patient need f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4103","BK4218","BK4510","BK4139","BK4220","BK4585","R","BK4539","BK4535","BK4215","PK","KSS","BK4597","IH","BK4547","BK4022","BK4563","NSS","ESS","CNTA","BK4181","BK4588","BK4085","BK4178","BK4232","AAN"],"gpt_icon":0},{"id":"2535572695","title":"Press Release: Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535572695","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535572695?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:00","pubTimestamp":1747134000,"startTime":"0","endTime":"0","summary":"-- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to. investigate sabirnetug  for the treatment of early Alzheimer's. -- Cash, cash equivalents and marketable securities of $197.9 million as of. March 31, 2025, expected to support current clinical and operational. NEWTON, Mass., May 13, 2025  -- Acumen Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers  for the treatment of Alzheimer's disease , today reported financial results for the first quarter of 2025 and provided a business update.sabirnetug on synaptic biomarkers in AD, methods of interrogating","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AAN","BK4178","ABOS","BK4139"],"gpt_icon":0},{"id":"2532881845","title":"Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532881845","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532881845?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:30","pubTimestamp":1746189000,"startTime":"0","endTime":"0","summary":"On track for six major study readouts across four programs over the next 12 months. Ready to initiate pivotal studies in two developmental and epileptic encephalopathy  programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen. Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability. Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link]. Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028. BOSTON, May 02, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","ASO","ET","BK4561","BK4588","TM","BK4144","BK4178","AAN","BK4139","BK4581","CNS","BK4604","BK4555","BK4135","BK4585","BK4099","BK4590","03160","PRAX","BK4200"],"gpt_icon":0},{"id":"2531793035","title":"Appendix 4C – Q3 FY25 Quarterly Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2531793035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531793035?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:35","pubTimestamp":1746012900,"startTime":"0","endTime":"0","summary":"Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy  led by robust clinical efficacy. Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting. ATH434-202 open-label trial in advanced MSA completed in March 2025. Cash balance on 31 March 2025 of A$17.96M with an additional A$27.1M raised subsequent to the end of the quarter. David Stamler, M.D., Chief Executive Officer of Alterity, commented, “The third fiscal quarter of 2025 was one of our most successful periods to date for Alterity Therapeutics. The outstanding results from our ATH434 Phase 2 double-blind trial continue to demonstrate the tremendous potential for ATH434 as a disease modifying treatment for MSA and are resonating throughout the medical community. For individuals living with MSA, there is currently no approved therapy to help stabilize or improve their condition, and we believe that ATH434 may be able to chang","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/appendix-4c-q3-fy25-quarterly-113500491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAN","LU2211815571.USD","MSA","BK4178","LU2125909759.SGD","ATH.AU","LU1815336091.USD","ATHE","BK4143","LU0728928796.USD","BK4139","LU1923622291.USD","LU0757428866.USD","LU0053671581.USD","LU2125909916.SGD"],"gpt_icon":0},{"id":"2527015710","title":"Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015710","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015710?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:15","pubTimestamp":1744632900,"startTime":"0","endTime":"0","summary":"Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune Diseases. The independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic’s neuroimmunology team, confirmed that ADI-100 induces immune tolerance to glutamic acid decarboxylase —a key autoantigen implicated in multiple autoimmune conditions, including type 1 diabetes, stiff person syndrome, cerebellar ataxia, and autoimmune epilepsy.\"These results mark an important milestone not only for Adimune’s platform but also for Aditxt’s broader vision of transforming the way we approach autoimmune diseases,\" said Amro Albanna, co-founder and CEO of Aditxt. \"We believe that autoimmunity represents one of the most underserved and challenging areas of medicine. ADI-100’s potential ability to restore immune tolerance without broad immunosuppression is a meaningful step toward safer, more targeted treatments.\". Immune Modulation at the Cellul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-adimune-announces-positive-121500858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0072461881.USD","LU2098885051.SGD","LU0162691827.USD","BK4139","BK4584","BK4178","EVFM","LU1267930490.SGD","BK4588","ADTX","LU0310799852.SGD","BK4007","LU0211328371.USD","LU1303367103.USD","LU0006061336.USD","LU0211327993.USD","BAX","BK4585","BK4504","BK4082","AAN"],"gpt_icon":0},{"id":"2526568284","title":"Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526568284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526568284?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:45","pubTimestamp":1744285557,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American Academy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-reports-new-data-from-ath434-phase-2-trial-at-aan-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-reports-new-data-from-ath434-phase-2-trial-at-aan-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","BK4007","BK4178","AAN","LENZ"],"gpt_icon":0},{"id":"2526550996","title":"Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550996","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550996?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:35","pubTimestamp":1744284900,"startTime":"0","endTime":"0","summary":"– Clinically Meaningful Efficacy Observed on Multiple Assessments –。– Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions –。Type: Oral Presentation Title: Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System AtrophyPresenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical CenterSummary: The oral presentation produced additional data on Alterity’s ATH434-201 Phase 2 clinical trial. Overall, the study results support continued advancement of ATH434 for the treatment of MSA. The imaging outcomes in n=61 participants indicate a heterogeneous localization of pathology and evidence that ATH434 reduces the iron signal in MSA affected brain regions. The clinical analysis included 71 patients who had at least one-post baseline UMSARS I assessment. The data showed that on the modified UMSARS I rating scale, ATH434 demonstrated a clinically significant treatment effect versu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-presents-encouraging-data-113500434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","MSA","BK4143","BK4007","LU0728928796.USD","LU0757428866.USD","BK4139","BK4107","LU0053671581.USD","TUG","BK4117","ATH.AU","AAN","BK4178","LU2125909916.SGD","LU1923622291.USD","LU2211815571.USD","LENZ","LU1815336091.USD","ATHE","LU2125909759.SGD"],"gpt_icon":0},{"id":"2526366907","title":"NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526366907","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526366907?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201800,"startTime":"0","endTime":"0","summary":"New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ --NeuroSense Therapeutics, Ltd. , a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company's investigational therapy for the treatment of amyotrophic lateral sclerosis , on microRNA  modulation.Represent an important development in understanding how the therapy may slow disease progression in people living with ALS.This research, conducted in collaboration with Prof. Noam Shomron of Tel Aviv University's Facultyof Medical and Health Sciences, a leader in microRNA research and functional genomics, was presented yesterday by Jeffrey Rosenfeld, M.D., Ph.D., Professor of Neurology and Associate Chairman of Neurology at Loma Lind","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-therapeutics-announces-transformative-phase-123000446.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-therapeutics-announces-transformative-phase-123000446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4178","BK4007","NRSN","NRSNW","AAN"],"gpt_icon":0},{"id":"2526680573","title":"Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2526680573","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526680573?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:53","pubTimestamp":1744199580,"startTime":"0","endTime":"0","summary":"In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology withgreater than 90% sensitivity and specificity. SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics , a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease  in patients with mild cognitive impairment  or dementia.In an oral presentation given this week at the American Academy of Neurology 's Annual Meeting in San Diego, Quest researchers presented data demonstrating that the new test would have a positive predictive value  of 89% and negative predictive value  of 89% in a population with mild cognitive impairment when the test cut offs were set at 91% sensitivity and 91% specificity. The addition of ApoE, a genetic risk marker, furth","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quest-diagnostics-launches-ad-detect-115300603.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quest-diagnostics-launches-ad-detect-115300603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4598","BK4583","BK4196","BK4567","BK4590","LU0029874061.USD","LU1854103824.USD","MCI","BK4178","LU1854104046.USD","AAN","AB","DGX","LU0128526141.USD","BK4135","BK4585"],"gpt_icon":0},{"id":"2526840473","title":"Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840473?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education C","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057993/0/en/Annexon-Highlights-Pivotal-Data-on-First-Potential-Targeted-Therapy-for-Guillain-Barr%C3%A9-Syndrome-GBS-and-Showcases-New-GBS-Education-Campaign-at-American-Academy-of-Neurology-AAN-20.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","AAN","ANNX","TUG","BK4178","GBSG","BK4117","BK4139","BK4107"],"gpt_icon":0},{"id":"2526846138","title":"Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846138","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846138?lang=en_us&edition=fundamental","pubTime":"2025-04-09 01:11","pubTimestamp":1744132260,"startTime":"0","endTime":"0","summary":"Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis. Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis. Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS. Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossieris under review in the EU with a decision expected in Q1 2026. The HERCULES data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression  by 31% compared to placebo . Additionally, results from the GEMINI 1 and 2 phase 3 studies, evaluating tolebrutinib in people with relapsing multiple sclerosis  were also published in NEJM and presented today during ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-tolebrutinib-phase-3-171100646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARR","BK4588","CDP","SNY","BK4007","BK4178","BK4223","AAN","BK4110","IE00BFXG1179.USD","BK4585"],"gpt_icon":0},{"id":"2525814141","title":"Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525814141","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525814141?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:00","pubTimestamp":1744124400,"startTime":"0","endTime":"0","summary":"CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057821/0/en/Cerevance-Presents-Positive-Results-from-Phase-1-Study-of-CVN293-at-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","BK4178","BK4117","BK4135","BK4107","CNS","AAN","AFG"],"gpt_icon":0},{"id":"2525892015","title":"Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2525892015","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525892015?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:05","pubTimestamp":1744113900,"startTime":"0","endTime":"0","summary":"Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting. PLYMOUTH MEETING, Pa., April 08, 2025----Harmony Biosciences Holdings, Inc.  today announced the presentation of updated data from its Open-Label Extension  study  evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome . The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration  approved treatments for FXS.\"The acceptance of our Fragile X syndrome OLE data as a podium presentation at AAN underlines the significant unmet need in FXS, and the potential for ZYN002 to become the first-and-only approved treatment for this condition,\" said Kumar Budur, MD, MS, Chief Medical and Scientific Officer at Harmony Biosciences. \"These data are encouraging as we prepare for the topline data read","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-presents-promising-open-120500495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4178","AAN","FXS","HRMY","BK4007"],"gpt_icon":0},{"id":"2525289956","title":"NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525289956","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525289956?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"NeuroPace RNS System   NeuroPace RNS System   Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term sei","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057542/0/en/NeuroPace-Announces-Data-From-a-Long-Term-Post-Approval-Study-of-the-RNS-System-in-Focal-Epilepsy-at-the-2025-AAN-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["POST","AAN","NPCE"],"gpt_icon":0},{"id":"2525501835","title":"argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP","url":"https://stock-news.laohu8.com/highlight/detail?id=2525501835","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525501835?lang=en_us&edition=fundamental","pubTime":"2025-04-08 13:00","pubTimestamp":1744088400,"startTime":"0","endTime":"0","summary":"ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057307/0/en/argenx-Highlights-VYVGART-Data-at-AAN-2025-Setting-New-Standard-in-Sustained-Efficacy-and-Improved-Quality-of-Life-Measures-for-Patients-Living-with-gMG-and-CIDP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2500361329.USD","AAN","LU2637428348.USD","LU2346227817.USD","BK4585","CMS","LU1894683264.USD","LU1894683348.USD","BK4208","BK4124","BK4588","BK4156","SMP","BK4178"],"gpt_icon":0},{"id":"2525301085","title":"Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525301085","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525301085?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"- Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients’ Parkinson’s Disease Sleep Scale-2  total and sub-scale scores. - Treatment with CREXONT also resulted in significantly more patients waking up in an \"On\" state compared to immediate-release CD/LD patients, as part of separate study analysis. BRIDGEWATER, N.J., April 07, 2025----Amneal Pharmaceuticals, Inc.  , a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed that patients who successfully converted to CREXONT from immediate release  carbidopa/levodopa  experienced statistically significant improvements in sleep quality. These improvements were measured by their Parkinson’s Disease Sleep Scale-2  total scores, showing a mean difference of -2.35 .A separate analysis of Hauser diary entries, which is a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN. Treatment w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amneal-announces-data-phase-3-120000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CD","BK4178","LU0124384867.USD","BK4588","IR","BK4023","LU0256863811.USD","BK4585","BK4135","LU0256863902.USD","LU1169590202.USD","BK4116","PD","SG9999001440.SGD","CNS","AMRX","LU0417517546.SGD","BK4007","AAN","LU1978683503.SGD","LU1169589451.USD","BK4161"],"gpt_icon":0},{"id":"2525017530","title":"Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017530","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017530?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"Presentation Title: \"Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue\" Poster Presentation Session: P-12 Poster Number: 11-017 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics. This poster describes the data around a novel breakthrough therapeutic  customized to a specific genetic mutation of a patient with Charcot-Marie-Tooth disease type 2S . The effects of VCA-894A were confirmed in Hesperos' Human-on-a-Chipneuromuscular junction model with patient-derived cells where VCA-894A demonstrated significant improvements in neuromuscular function, including reduced muscle fatigue and improved synaptic transmission between motor neurons and skeletal muscle myotubes. The use of a microphysiological system to evaluate the effects of a genetically tailored treatment represents a significant advancement in precision medicine and the use of human relevant methods of evaluation.VCA-894A has been granted an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/vanda-pharmaceuticals-announces-presentation-2025-120000402.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vanda-pharmaceuticals-announces-presentation-2025-120000402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAN","BK4178","VNDA","BK4139"],"gpt_icon":0},{"id":"2525571856","title":"Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525571856","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525571856?lang=en_us&edition=fundamental","pubTime":"2025-04-05 21:00","pubTimestamp":1743858000,"startTime":"0","endTime":"0","summary":"SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ --Biohaven Ltd. announced today that it will present 13 abstracts at the 2025 American Academy of Neurology  Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation.Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, \"We are excited to highlight our clinical and scientific progress at the AAN Annual Meeting, including 3 oral presentations and 10 poster presentations, emphasizing Biohaven's innovation, leadership and commitment to developing potential first-in-class therapies for debilitating neurological disorders with inadequate or no treatment options. The team at Biohaven has been working urgently to advance our next-g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biohaven-presents-data-across-innovative-130000816.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biohaven-presents-data-across-innovative-130000816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAN","LU1093756168.USD","BK4178","BK4107","LU1093756325.SGD","BK4139","AFG","SCA","BHVN","BK4117"],"gpt_icon":0},{"id":"2524620415","title":"Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524620415","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524620415?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:10","pubTimestamp":1743772201,"startTime":"0","endTime":"0","summary":"Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals announced that it will present long-term data on its drug azetukalner at the Ameri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-promising-azetukalner-data-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-promising-azetukalner-data-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4178","BK4139","AAN","XENE"],"gpt_icon":0},{"id":"2524204220","title":"NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524204220","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524204220?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:10","pubTimestamp":1743772200,"startTime":"0","endTime":"0","summary":"Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense. Jeremy Shefner, M.D., Ph.D., Chair of the Department of Neurology and Senior Vice President at the Barrow Neurological Institute, will present new, compelling data from the Phase 2b trial of PrimeC, NeuroSense's novel investigational therapy for amyotrophic lateral sclerosis , at 2:24 p.m. His presentation, \"Shifting the Paradigm: PrimeC, an Oral Candidate for ALS, Demonstrates Safety, Efficacy, and Target Engagement in an 18-Month Phase 2b Trial,\" will highlight PrimeC's disease-modifying potential in ALS treatment.\"This exciting Phase 2b trial data underscores PrimeC's potential to redefine ALS treatment,\" says Shefner. \"By demonstrating safety and tolerability, an indication of marked reduction in ALS progression, and multiple biomarker endpoints establishing PrimeC's biological activity, we move closer to offering a disease-modifying therapy t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-therapeutics-present-data-primecs-131000174.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-therapeutics-present-data-primecs-131000174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","NRSN","AFG","BK4117","NRSNW","BK4178","LENZ","AAN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-10-04","symbol":"AAN","reason":null,"defaultRemindTime":1728048600000,"announcedDate":"2024-09-20","type":"delisting","dateTimestamp":1728014400000},{"date":"2024-09-13","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-13","defaultRemindTime":1726234200000,"name":"The Aaron's Company, Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-09-13","currency":"USD","dateTimestamp":1726200000000,"payDate":"2024-10-03"},{"date":"2024-08-05","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.03,"defaultRemindTime":1722888000000,"name":null,"time":"Post Market","dateTimestamp":1722830400000,"actualEps":null},{"date":"2024-06-14","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-06-14","defaultRemindTime":1718371800000,"name":"The Aaron's Company, Inc.","recordDate":"2024-07-03","payableDate":"2024-06-14","currency":"USD","dateTimestamp":1718337600000,"payDate":"2024-07-03"},{"date":"2024-05-06","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":-0.08,"defaultRemindTime":1715025600000,"name":null,"time":"Post Market","dateTimestamp":1714968000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAN\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-13","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-06-23","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-09-14","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-12-12","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"},{"executeDate":"2018-03-22","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":7,"updateTime":1720670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAN","date":"2024-10-02","current":-7.155926,"percent":0.311436,"low":-226.61145,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"high":112.497555,"avg":-0.454661,"sd":44.674017,"marketCap":304670698},"quantilePoints":[{"date":"2020-06-05","current":-10.108748,"twenty":12.666915,"median":14.697246,"eighty":55.285946,"marketCap":3079235898},{"date":"2020-06-12","current":-9.660654,"twenty":12.694892,"median":14.714231,"eighty":60.33638,"marketCap":2942741350},{"date":"2020-06-19","current":-9.374494,"twenty":12.706944,"median":14.728744,"eighty":64.235874,"marketCap":2855574041},{"date":"2020-06-26","current":-9.831462,"twenty":12.727173,"median":14.743696,"eighty":68.885595,"marketCap":2994771450},{"date":"2020-07-02","current":-9.922412,"twenty":12.757734,"median":14.760452,"eighty":74.680396,"marketCap":3022475789},{"date":"2020-07-10","current":-9.718329,"twenty":12.780116,"median":14.769223,"eighty":82.671415,"marketCap":2960309955},{"date":"2020-07-17","current":-9.76935,"twenty":12.808093,"median":14.806954,"eighty":91.048411,"marketCap":2975851414},{"date":"2020-07-24","current":-9.968996,"twenty":12.82574,"median":14.866761,"eighty":-10.859861,"marketCap":3036665816},{"date":"2020-07-31","current":-12.701825,"twenty":12.834349,"median":14.893301,"eighty":-10.268021,"marketCap":3542335892},{"date":"2020-08-07","current":-13.074984,"twenty":12.839514,"median":14.903566,"eighty":-10.577251,"marketCap":3646403759},{"date":"2020-08-14","current":-14.062047,"twenty":12.883417,"median":15.075972,"eighty":-10.859861,"marketCap":3921680051},{"date":"2020-08-21","current":-13.655185,"twenty":12.929473,"median":15.897669,"eighty":-11.826229,"marketCap":3808212506},{"date":"2020-08-28","current":-13.703334,"twenty":12.954868,"median":16.208979,"eighty":-12.506339,"marketCap":3821640618},{"date":"2020-09-04","current":-13.39277,"twenty":12.981123,"median":16.624181,"eighty":-12.566525,"marketCap":3735029297},{"date":"2020-09-11","current":-14.247423,"twenty":12.992314,"median":17.026732,"eighty":-12.622378,"marketCap":3973378281},{"date":"2020-09-18","current":-13.662407,"twenty":13.056878,"median":17.41088,"eighty":-12.80968,"marketCap":3810226723},{"date":"2020-09-25","current":-13.096651,"twenty":13.174383,"median":17.72832,"eighty":-13.012871,"marketCap":3652446409},{"date":"2020-10-02","current":-13.525181,"twenty":13.207096,"median":17.868637,"eighty":-13.083651,"marketCap":3771956604},{"date":"2020-10-09","current":-14.379834,"twenty":13.214843,"median":33.338326,"eighty":-13.117837,"marketCap":4010305589},{"date":"2020-10-16","current":-14.322055,"twenty":13.224312,"median":38.979544,"eighty":-13.152023,"marketCap":3994191854},{"date":"2020-10-23","current":-14.134272,"twenty":13.267355,"median":41.25936,"eighty":-13.164982,"marketCap":3941822218},{"date":"2020-10-30","current":-13.18332,"twenty":13.431346,"median":46.359785,"eighty":-13.174612,"marketCap":3676617010},{"date":"2020-11-06","current":-13.890074,"twenty":13.510113,"median":48.066995,"eighty":-13.16406,"marketCap":3873719412},{"date":"2020-11-13","current":-18.86588,"twenty":13.554877,"median":49.399254,"eighty":-13.174612,"marketCap":3949383272},{"date":"2020-11-20","current":-20.234189,"twenty":13.740165,"median":50.045957,"eighty":-13.179304,"marketCap":4235825028},{"date":"2020-11-27","current":-3.0341,"twenty":12.60063,"median":14.406704,"eighty":14.852959,"marketCap":753260750},{"date":"2020-12-04","current":-2.585107,"twenty":12.532192,"median":14.373349,"eighty":14.823056,"marketCap":641791671},{"date":"2020-12-11","current":-2.410953,"twenty":12.484845,"median":14.29399,"eighty":14.806494,"marketCap":598555179},{"date":"2020-12-18","current":-2.470818,"twenty":12.40823,"median":14.223831,"eighty":14.790852,"marketCap":613417723},{"date":"2020-12-24","current":-2.283058,"twenty":12.321715,"median":14.182426,"eighty":14.77668,"marketCap":566803381},{"date":"2020-12-31","current":-2.579665,"twenty":12.263178,"median":14.155973,"eighty":14.768028,"marketCap":640440530},{"date":"2021-01-08","current":-2.747017,"twenty":-12.767253,"median":12.412319,"eighty":14.892168,"marketCap":681988096},{"date":"2021-01-15","current":-2.921171,"twenty":-12.676425,"median":12.394026,"eighty":14.876492,"marketCap":725224588},{"date":"2021-01-22","current":-2.816406,"twenty":-12.623461,"median":12.34668,"eighty":14.868142,"marketCap":699215136},{"date":"2021-01-29","current":-2.304827,"twenty":-12.566525,"median":12.314398,"eighty":14.85756,"marketCap":572207942},{"date":"2021-02-05","current":-2.670824,"twenty":-12.506339,"median":12.260595,"eighty":14.829956,"marketCap":663072131},{"date":"2021-02-12","current":-2.717084,"twenty":-11.826229,"median":12.245531,"eighty":14.807414,"marketCap":674556824},{"date":"2021-02-19","current":-2.880354,"twenty":-10.895798,"median":12.221858,"eighty":14.800053,"marketCap":715091035},{"date":"2021-02-26","current":-2.824769,"twenty":-10.664651,"median":12.178815,"eighty":14.779165,"marketCap":751139845},{"date":"2021-03-05","current":-3.082033,"twenty":-10.291535,"median":12.103491,"eighty":14.768028,"marketCap":819549667},{"date":"2021-03-12","current":-3.265978,"twenty":-10.182396,"median":11.879671,"eighty":14.76305,"marketCap":868462690},{"date":"2021-03-19","current":-3.326435,"twenty":-10.119396,"median":-2.281017,"eighty":14.761535,"marketCap":884538998},{"date":"2021-03-26","current":-3.343157,"twenty":-10.105642,"median":-2.304827,"eighty":14.756348,"marketCap":888985636},{"date":"2021-04-01","current":-3.34573,"twenty":-10.09322,"median":-2.344284,"eighty":14.747146,"marketCap":889669735},{"date":"2021-04-09","current":-3.17079,"twenty":-10.071037,"median":-2.386462,"eighty":14.740245,"marketCap":843151056},{"date":"2021-04-16","current":-3.285273,"twenty":-10.046636,"median":-2.443607,"eighty":14.729751,"marketCap":873593426},{"date":"2021-04-23","current":-3.316144,"twenty":-10.020017,"median":-2.447688,"eighty":14.728744,"marketCap":881802605},{"date":"2021-04-30","current":11.206787,"twenty":-9.991179,"median":-2.446328,"eighty":14.725108,"marketCap":1055511238},{"date":"2021-05-07","current":11.685679,"twenty":-9.968996,"median":-2.40415,"eighty":14.71582,"marketCap":1100615635},{"date":"2021-05-14","current":11.816285,"twenty":-9.960123,"median":-2.352448,"eighty":14.712642,"marketCap":1112916834},{"date":"2021-05-21","current":12.614438,"twenty":-9.922412,"median":-2.317753,"eighty":14.704211,"marketCap":1188090830},{"date":"2021-05-28","current":13.049794,"twenty":-9.922412,"median":-2.283058,"eighty":14.697246,"marketCap":1229094828},{"date":"2021-06-04","current":13.125981,"twenty":-9.917088,"median":-2.227274,"eighty":14.68932,"marketCap":1236270527},{"date":"2021-06-11","current":13.260216,"twenty":-9.867842,"median":11.159624,"eighty":14.667402,"marketCap":1248913426},{"date":"2021-06-18","current":12.57453,"twenty":-9.84699,"median":11.239439,"eighty":14.64187,"marketCap":1184332130},{"date":"2021-06-25","current":11.965032,"twenty":-9.834124,"median":11.357348,"eighty":14.634991,"marketCap":1126926534},{"date":"2021-07-02","current":11.732842,"twenty":-9.829688,"median":11.551444,"eighty":14.634457,"marketCap":1105057735},{"date":"2021-07-09","current":11.174135,"twenty":-9.803955,"median":11.36279,"eighty":14.630291,"marketCap":1052435938},{"date":"2021-07-16","current":10.038588,"twenty":-9.784434,"median":11.319254,"eighty":14.62063,"marketCap":945484414},{"date":"2021-07-23","current":9.724994,"twenty":-9.774674,"median":11.228555,"eighty":14.598088,"marketCap":915948515},{"date":"2021-07-30","current":9.001746,"twenty":-9.75604,"median":11.175949,"eighty":14.583366,"marketCap":943256951},{"date":"2021-08-06","current":8.621347,"twenty":-9.731195,"median":11.141484,"eighty":14.569104,"marketCap":903396422},{"date":"2021-08-13","current":9.117113,"twenty":-9.719216,"median":10.680732,"eighty":14.542881,"marketCap":955345800},{"date":"2021-08-20","current":8.764776,"twenty":-9.702358,"median":10.238148,"eighty":14.515087,"marketCap":918425802},{"date":"2021-08-27","current":8.602638,"twenty":-9.686386,"median":10.004734,"eighty":14.503803,"marketCap":901436068},{"date":"2021-09-03","current":8.371904,"twenty":-9.670858,"median":9.878227,"eighty":14.495035,"marketCap":877258370},{"date":"2021-09-10","current":8.178587,"twenty":-9.661985,"median":9.724994,"eighty":14.487674,"marketCap":857001379},{"date":"2021-09-17","current":8.396849,"twenty":-9.651781,"median":9.151412,"eighty":14.481233,"marketCap":879872175},{"date":"2021-09-24","current":8.580812,"twenty":-9.63226,"median":9.001746,"eighty":14.46099,"marketCap":899148988},{"date":"2021-10-01","current":8.761658,"twenty":-9.601647,"median":8.958094,"eighty":14.437068,"marketCap":918099076},{"date":"2021-10-08","current":8.714887,"twenty":-9.542197,"median":8.892615,"eighty":14.434307,"marketCap":913198191},{"date":"2021-10-15","current":8.56834,"twenty":-9.495613,"median":8.813105,"eighty":14.433387,"marketCap":897842086},{"date":"2021-10-22","current":9.447624,"twenty":-9.47343,"median":8.883261,"eighty":14.431087,"marketCap":989978719},{"date":"2021-10-29","current":7.629357,"twenty":-9.434388,"median":8.8209,"eighty":14.420506,"marketCap":736393147},{"date":"2021-11-05","current":8.350215,"twenty":-9.394459,"median":8.792838,"eighty":14.39847,"marketCap":805971123},{"date":"2021-11-12","current":8.568756,"twenty":-9.349649,"median":8.764776,"eighty":14.382391,"marketCap":827064898},{"date":"2021-11-19","current":8.239314,"twenty":-9.109187,"median":8.724241,"eighty":14.37404,"marketCap":795266819},{"date":"2021-11-26","current":7.847898,"twenty":-8.748937,"median":8.714887,"eighty":14.357938,"marketCap":757486922},{"date":"2021-12-03","current":7.440172,"twenty":-8.524445,"median":8.691502,"eighty":14.306872,"marketCap":718132864},{"date":"2021-12-10","current":7.94249,"twenty":-8.467214,"median":8.668117,"eighty":14.283409,"marketCap":766617064},{"date":"2021-12-17","current":7.844636,"twenty":-8.262243,"median":8.662471,"eighty":14.239703,"marketCap":757172090},{"date":"2021-12-23","current":7.988155,"twenty":-8.187709,"median":8.61667,"eighty":14.234182,"marketCap":771024719},{"date":"2021-12-31","current":8.040344,"twenty":-8.054612,"median":8.608874,"eighty":14.21348,"marketCap":776062038},{"date":"2022-01-07","current":7.74352,"twenty":-8.039083,"median":8.604197,"eighty":14.188176,"marketCap":747412283},{"date":"2022-01-14","current":7.489099,"twenty":-7.937042,"median":8.587048,"eighty":14.176675,"marketCap":722855351},{"date":"2022-01-21","current":6.954164,"twenty":-7.711664,"median":8.580812,"eighty":14.163793,"marketCap":671222826},{"date":"2022-01-28","current":6.771503,"twenty":-7.561264,"median":8.568548,"eighty":14.153212,"marketCap":653592207},{"date":"2022-02-04","current":6.774764,"twenty":-7.498708,"median":8.50598,"eighty":14.13849,"marketCap":653907040},{"date":"2022-02-11","current":6.800859,"twenty":-7.4783,"median":8.402672,"eighty":14.109507,"marketCap":656425699},{"date":"2022-02-18","current":6.85631,"twenty":-7.417075,"median":8.390613,"eighty":14.090805,"marketCap":661777851},{"date":"2022-02-25","current":6.0444,"twenty":-7.399772,"median":8.371904,"eighty":14.073473,"marketCap":664485049},{"date":"2022-03-04","current":6.303647,"twenty":-7.338104,"median":8.35837,"eighty":14.046019,"marketCap":692985107},{"date":"2022-03-11","current":6.154298,"twenty":-7.214323,"median":8.322016,"eighty":14.028536,"marketCap":676566596},{"date":"2022-03-18","current":6.531897,"twenty":-7.133134,"median":8.300596,"eighty":14.016575,"marketCap":718077550},{"date":"2022-03-25","current":6.358874,"twenty":-7.012459,"median":8.278364,"eighty":13.990352,"marketCap":699056405},{"date":"2022-04-01","current":5.853417,"twenty":-6.728961,"median":8.262316,"eighty":13.959988,"marketCap":643489564},{"date":"2022-04-08","current":6.111955,"twenty":-4.797768,"median":8.237829,"eighty":13.929624,"marketCap":671911684},{"date":"2022-04-14","current":6.210723,"twenty":-3.54381,"median":8.229529,"eighty":13.89558,"marketCap":682769573},{"date":"2022-04-22","current":5.94928,"twenty":-3.437831,"median":8.209791,"eighty":13.857395,"marketCap":654028103},{"date":"2022-04-29","current":6.626359,"twenty":-3.415191,"median":8.180601,"eighty":13.79395,"marketCap":630451705},{"date":"2022-05-06","current":6.539213,"twenty":-3.410303,"median":8.142587,"eighty":13.634075,"marketCap":622160328},{"date":"2022-05-13","current":6.452066,"twenty":-3.405158,"median":8.086009,"eighty":13.512696,"marketCap":613868951},{"date":"2022-05-20","current":5.864635,"twenty":-3.380718,"median":8.051782,"eighty":13.496451,"marketCap":557978932},{"date":"2022-05-27","current":6.077659,"twenty":-3.349589,"median":8.001202,"eighty":13.451527,"marketCap":578246741},{"date":"2022-06-03","current":5.961464,"twenty":-3.34573,"median":7.971846,"eighty":13.396862,"marketCap":567191572},{"date":"2022-06-10","current":5.796854,"twenty":-3.345215,"median":7.947382,"eighty":13.321166,"marketCap":551530083},{"date":"2022-06-17","current":5.060951,"twenty":-3.339813,"median":7.90661,"eighty":13.254413,"marketCap":481514015},{"date":"2022-06-24","current":5.222333,"twenty":-3.326435,"median":7.860945,"eighty":13.231199,"marketCap":496868416},{"date":"2022-07-01","current":4.760779,"twenty":-3.316144,"median":7.81528,"eighty":13.22259,"marketCap":452954829},{"date":"2022-07-08","current":4.947983,"twenty":-3.305854,"median":7.76146,"eighty":13.21226,"marketCap":470765934},{"date":"2022-07-15","current":4.734958,"twenty":-3.289903,"median":7.704378,"eighty":13.206235,"marketCap":450498125},{"date":"2022-07-22","current":5.167463,"twenty":-3.28553,"median":7.670129,"eighty":13.197004,"marketCap":491647920},{"date":"2022-07-29","current":7.051656,"twenty":-3.278069,"median":7.648928,"eighty":13.194912,"marketCap":400717386},{"date":"2022-08-05","current":7.214136,"twenty":-3.275239,"median":7.552705,"eighty":13.171694,"marketCap":409950505},{"date":"2022-08-12","current":7.907387,"twenty":-3.267779,"median":7.629357,"eighty":13.156156,"marketCap":449345149},{"date":"2022-08-19","current":7.598674,"twenty":-3.244368,"median":7.653821,"eighty":13.131529,"marketCap":431802221},{"date":"2022-08-26","current":6.932503,"twenty":-3.236907,"median":7.598674,"eighty":13.111469,"marketCap":393946432},{"date":"2022-09-02","current":6.428814,"twenty":-3.219927,"median":7.549929,"eighty":13.107841,"marketCap":365323761},{"date":"2022-09-09","current":6.640038,"twenty":-3.21118,"median":7.533133,"eighty":13.099134,"marketCap":377326816},{"date":"2022-09-16","current":6.612958,"twenty":-3.207321,"median":7.484937,"eighty":13.091152,"marketCap":375787963},{"date":"2022-09-23","current":5.8493,"twenty":-3.205263,"median":7.456481,"eighty":13.087524,"marketCap":332392302},{"date":"2022-09-30","current":5.26437,"twenty":-3.201919,"median":7.440172,"eighty":13.068659,"marketCap":299153071},{"date":"2022-10-07","current":5.145217,"twenty":-3.198832,"median":7.301545,"eighty":13.052696,"marketCap":292382117},{"date":"2022-10-14","current":4.798592,"twenty":-3.190085,"median":7.23794,"eighty":13.04544,"marketCap":272684795},{"date":"2022-10-21","current":4.717352,"twenty":-3.17645,"median":7.204836,"eighty":13.012404,"marketCap":268068236},{"date":"2022-10-28","current":18.856739,"twenty":-3.156126,"median":7.23794,"eighty":13.087524,"marketCap":317962337},{"date":"2022-11-04","current":17.72497,"twenty":-3.141719,"median":7.301545,"eighty":13.115097,"marketCap":298878441},{"date":"2022-11-11","current":20.882972,"twenty":-3.13786,"median":7.440172,"eighty":13.194912,"marketCap":352128668},{"date":"2022-11-18","current":20.171052,"twenty":-3.129627,"median":7.456481,"eighty":13.226034,"marketCap":340124281},{"date":"2022-11-25","current":21.138532,"twenty":-3.119851,"median":7.477233,"eighty":13.381747,"marketCap":356437935},{"date":"2022-12-02","current":22.945713,"twenty":-3.112391,"median":7.528241,"eighty":13.634075,"marketCap":386910608},{"date":"2022-12-09","current":21.412348,"twenty":-3.103901,"median":7.549929,"eighty":13.936064,"marketCap":361055006},{"date":"2022-12-16","current":21.722672,"twenty":-3.091295,"median":7.598674,"eighty":14.030377,"marketCap":366287688},{"date":"2022-12-23","current":20.755191,"twenty":-3.086664,"median":7.653821,"eighty":14.122388,"marketCap":349974034},{"date":"2022-12-30","current":21.813943,"twenty":-3.077344,"median":7.683177,"eighty":14.173455,"marketCap":367826712},{"date":"2023-01-06","current":23.821921,"twenty":-3.05859,"median":7.720687,"eighty":14.234182,"marketCap":401685237},{"date":"2023-01-13","current":26.194986,"twenty":-3.050427,"median":7.750322,"eighty":14.369899,"marketCap":441699859},{"date":"2023-01-20","current":25.884662,"twenty":-3.037365,"median":7.785923,"eighty":14.411305,"marketCap":436467178},{"date":"2023-01-27","current":26.158478,"twenty":-2.983948,"median":7.846267,"eighty":14.435227,"marketCap":441084249},{"date":"2023-02-03","current":28.239473,"twenty":-2.934484,"median":7.860945,"eighty":14.492274,"marketCap":476173994},{"date":"2023-02-10","current":26.724362,"twenty":-2.921987,"median":7.903348,"eighty":14.564964,"marketCap":450626197},{"date":"2023-02-17","current":26.92516,"twenty":-2.910286,"median":7.907387,"eighty":14.628911,"marketCap":454012050},{"date":"2023-02-24","current":25.793391,"twenty":-2.891238,"median":7.922919,"eighty":14.647007,"marketCap":434928154},{"date":"2023-03-03","current":-74.11349,"twenty":-2.922804,"median":7.915153,"eighty":14.672386,"marketCap":391319229},{"date":"2023-03-10","current":-64.718823,"twenty":-3.053692,"median":7.907387,"eighty":14.647007,"marketCap":341715383},{"date":"2023-03-17","current":-54.86022,"twenty":-3.100042,"median":7.890196,"eighty":14.635427,"marketCap":289661964},{"date":"2023-03-24","current":-55.522605,"twenty":-3.13786,"median":7.853226,"eighty":14.634482,"marketCap":293159356},{"date":"2023-03-31","current":-58.235436,"twenty":-3.190085,"median":7.835391,"eighty":14.630291,"marketCap":307483103},{"date":"2023-04-06","current":-57.512015,"twenty":-3.205778,"median":7.782661,"eighty":14.622931,"marketCap":303663437},{"date":"2023-04-14","current":-64.62566,"twenty":-3.237936,"median":7.74352,"eighty":14.604068,"marketCap":341223485},{"date":"2023-04-21","current":-62.214255,"twenty":-3.281671,"median":7.694593,"eighty":14.584286,"marketCap":328491265},{"date":"2023-04-28","current":-29.179552,"twenty":-3.322319,"median":7.658713,"eighty":14.573245,"marketCap":408922246},{"date":"2023-05-05","current":-26.224103,"twenty":-3.349589,"median":7.614015,"eighty":14.548861,"marketCap":367504573},{"date":"2023-05-12","current":-27.701827,"twenty":-3.415191,"median":7.555345,"eighty":14.520365,"marketCap":388213410},{"date":"2023-05-19","current":-28.650218,"twenty":-6.80039,"median":7.533133,"eighty":14.504046,"marketCap":401504155},{"date":"2023-05-26","current":-27.282771,"twenty":-7.358069,"median":7.484937,"eighty":14.497795,"marketCap":382340755},{"date":"2023-06-02","current":-27.018104,"twenty":-7.486286,"median":7.459743,"eighty":14.488594,"marketCap":378631709},{"date":"2023-06-09","current":-31.782113,"twenty":-8.018675,"median":7.446307,"eighty":14.483074,"marketCap":445394525},{"date":"2023-06-16","current":-30.017665,"twenty":-8.467214,"median":7.348842,"eighty":14.468351,"marketCap":420667556},{"date":"2023-06-23","current":-28.716385,"twenty":-9.312382,"median":7.241202,"eighty":14.438908,"marketCap":402431417},{"date":"2023-06-30","current":-31.605668,"twenty":-9.459233,"median":7.224968,"eighty":14.435227,"marketCap":442921828},{"date":"2023-07-07","current":-31.892391,"twenty":-9.591,"median":7.195537,"eighty":14.434307,"marketCap":446939961},{"date":"2023-07-14","current":-33.083393,"twenty":-9.670858,"median":7.136824,"eighty":14.432927,"marketCap":463630665},{"date":"2023-07-21","current":-34.340562,"twenty":-9.731195,"median":7.111232,"eighty":14.430627,"marketCap":481248630},{"date":"2023-07-28","current":-33.921505,"twenty":-9.803955,"median":7.051837,"eighty":14.415905,"marketCap":475375975},{"date":"2023-08-04","current":-188.365396,"twenty":-9.879821,"median":7.029992,"eighty":14.394353,"marketCap":405927428},{"date":"2023-08-11","current":-189.224858,"twenty":-9.963672,"median":6.998198,"eighty":14.380528,"marketCap":407779569},{"date":"2023-08-18","current":-177.90861,"twenty":-10.056396,"median":6.986782,"eighty":14.372659,"marketCap":383393054},{"date":"2023-08-25","current":-170.316697,"twenty":-10.152227,"median":6.952533,"eighty":14.334015,"marketCap":367032481},{"date":"2023-09-01","current":-172.895082,"twenty":-11.528064,"median":6.932503,"eighty":14.300431,"marketCap":372588902},{"date":"2023-09-08","current":-145.392302,"twenty":-12.623461,"median":6.905237,"eighty":14.272827,"marketCap":313320410},{"date":"2023-09-15","current":-149.25988,"twenty":-13.033575,"median":6.884571,"eighty":14.238323,"marketCap":321655042},{"date":"2023-09-22","current":-152.697728,"twenty":-13.168875,"median":6.85631,"eighty":14.225901,"marketCap":329063603},{"date":"2023-09-29","current":-152.41124,"twenty":-13.297434,"median":6.830215,"eighty":14.203358,"marketCap":328446223},{"date":"2023-10-06","current":-140.665261,"twenty":-13.435141,"median":6.802519,"eighty":14.183576,"marketCap":303133638},{"date":"2023-10-13","current":-136.797683,"twenty":-13.525181,"median":6.773134,"eighty":14.170234,"marketCap":294799007},{"date":"2023-10-20","current":-133.646323,"twenty":-13.584405,"median":6.745664,"eighty":14.158733,"marketCap":288007825},{"date":"2023-10-27","current":23.778109,"twenty":-13.598368,"median":6.745664,"eighty":14.167014,"marketCap":221707087},{"date":"2023-11-03","current":23.680524,"twenty":-13.577664,"median":6.774764,"eighty":14.236942,"marketCap":220797209},{"date":"2023-11-10","current":22.346868,"twenty":-13.547812,"median":6.803199,"eighty":14.372659,"marketCap":208362201},{"date":"2023-11-17","current":27.909189,"twenty":-13.52807,"median":6.836739,"eighty":14.430627,"marketCap":260225282},{"date":"2023-11-24","current":28.917563,"twenty":-13.525181,"median":6.85631,"eighty":14.437068,"marketCap":269627361},{"date":"2023-12-01","current":28.657338,"twenty":-13.505446,"median":6.884571,"eighty":14.497795,"marketCap":267201018},{"date":"2023-12-08","current":34.02449,"twenty":-13.470998,"median":6.905237,"eighty":14.573245,"marketCap":317244342},{"date":"2023-12-15","current":38.123042,"twenty":-13.460384,"median":6.940627,"eighty":14.631672,"marketCap":355459243},{"date":"2023-12-22","current":36.333991,"twenty":-13.435141,"median":6.954164,"eighty":14.677371,"marketCap":338778135},{"date":"2023-12-29","current":36.333991,"twenty":-13.404807,"median":6.970474,"eighty":14.704211,"marketCap":338778135},{"date":"2024-01-05","current":36.952027,"twenty":-13.397585,"median":6.991083,"eighty":14.719535,"marketCap":344540700},{"date":"2024-01-12","current":35.423202,"twenty":-13.386992,"median":7.016542,"eighty":14.743005,"marketCap":330285935},{"date":"2024-01-19","current":33.308869,"twenty":-13.35425,"median":7.040824,"eighty":14.762852,"marketCap":310571898},{"date":"2024-01-26","current":34.870223,"twenty":-13.297434,"median":7.052018,"eighty":14.7972,"marketCap":325129956},{"date":"2024-02-02","current":33.66668,"twenty":-13.239655,"median":7.119356,"eighty":14.868142,"marketCap":313908120},{"date":"2024-02-09","current":33.991961,"twenty":-13.181312,"median":7.140086,"eighty":14.902766,"marketCap":316941049},{"date":"2024-02-16","current":35.228033,"twenty":-13.176456,"median":7.204836,"eighty":15.530992,"marketCap":328466178},{"date":"2024-02-23","current":33.146228,"twenty":-13.171283,"median":7.231454,"eighty":16.007704,"marketCap":309055434},{"date":"2024-03-01","current":83.351439,"twenty":-13.159245,"median":7.254249,"eighty":16.944381,"marketCap":235301113},{"date":"2024-03-08","current":77.221075,"twenty":-13.139022,"median":7.397562,"eighty":17.504731,"marketCap":217995096},{"date":"2024-03-15","current":74.74742,"twenty":-13.092318,"median":7.453219,"eighty":17.739361,"marketCap":211011966},{"date":"2024-03-22","current":81.364368,"twenty":-13.05428,"median":7.477233,"eighty":17.972015,"marketCap":229691610},{"date":"2024-03-28","current":80.387995,"twenty":-12.971462,"median":7.50867,"eighty":18.290855,"marketCap":226935310},{"date":"2024-04-05","current":78.760708,"twenty":-12.865396,"median":7.544513,"eighty":18.783722,"marketCap":222341478},{"date":"2024-04-12","current":77.458878,"twenty":-12.701825,"median":7.583029,"eighty":19.185317,"marketCap":218666412},{"date":"2024-04-19","current":79.303137,"twenty":-12.659492,"median":7.648928,"eighty":20.171052,"marketCap":223872755},{"date":"2024-04-26","current":79.411623,"twenty":-12.569414,"median":7.683177,"eighty":20.718683,"marketCap":224179011},{"date":"2024-05-03","current":73.661874,"twenty":-12.562192,"median":7.736996,"eighty":20.882972,"marketCap":207947470},{"date":"2024-05-10","current":-9.41993,"twenty":-12.422559,"median":7.694593,"eighty":20.882972,"marketCap":227547821},{"date":"2024-05-17","current":-9.55939,"twenty":-10.931734,"median":7.658713,"eighty":20.755191,"marketCap":230916631},{"date":"2024-05-24","current":-9.064939,"twenty":-10.752052,"median":7.614015,"eighty":20.736937,"marketCap":218972668},{"date":"2024-05-31","current":-9.77492,"twenty":-10.40245,"median":7.561364,"eighty":20.736937,"marketCap":236122975},{"date":"2024-06-07","current":-10.751145,"twenty":-10.751145,"median":7.538026,"eighty":20.722334,"marketCap":259704647},{"date":"2024-06-14","current":-9.812955,"twenty":-10.735931,"median":7.489099,"eighty":20.685825,"marketCap":237041741},{"date":"2024-06-21","current":-13.023365,"twenty":-10.751689,"median":7.469528,"eighty":20.598203,"marketCap":314592404},{"date":"2024-06-28","current":-12.984217,"twenty":-10.787988,"median":7.459743,"eighty":20.532488,"marketCap":313646735},{"date":"2024-07-05","current":-13.036414,"twenty":-12.56797,"median":7.440172,"eighty":20.433914,"marketCap":314907627},{"date":"2024-07-12","current":-12.997266,"twenty":-12.950249,"median":7.23794,"eighty":20.433914,"marketCap":313961958},{"date":"2024-07-15","current":-13.036414,"twenty":-12.981666,"median":7.224968,"eighty":20.433914,"marketCap":314907627},{"date":"2024-08-02","current":-13.127761,"twenty":-13.007706,"median":7.086518,"eighty":20.725985,"marketCap":317114187},{"date":"2024-08-09","current":-7.228062,"twenty":-13.023365,"median":7.029992,"eighty":20.725985,"marketCap":307741975},{"date":"2024-08-16","current":-7.271344,"twenty":-13.023365,"median":6.970474,"eighty":20.725985,"marketCap":309584741},{"date":"2024-08-23","current":-7.26413,"twenty":-13.023365,"median":6.9205,"eighty":20.725985,"marketCap":309277614},{"date":"2024-08-30","current":-7.278558,"twenty":-13.023365,"median":6.879843,"eighty":20.725985,"marketCap":309891869},{"date":"2024-09-06","current":-7.206421,"twenty":-13.023365,"median":6.830215,"eighty":20.725985,"marketCap":306820592},{"date":"2024-09-13","current":-7.292985,"twenty":-13.023365,"median":6.773134,"eighty":20.725985,"marketCap":310506124},{"date":"2024-09-20","current":-7.242489,"twenty":-13.023365,"median":6.654179,"eighty":20.725985,"marketCap":308356230},{"date":"2024-09-27","current":-7.235276,"twenty":-13.023365,"median":6.602126,"eighty":20.725985,"marketCap":308049103},{"date":"2024-10-02","current":-7.155926,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"marketCap":304670698}],"updateTime":1749035063377}}}